Our top pick for
Biomerica Inc is a diagnostics & research business based in the US. Biomerica shares (BMRA) are listed on the NASDAQ and all prices are listed in US Dollars. Biomerica employs 66 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$5.12|
|52-week range||$3.30 - $8.15|
|50-day moving average||$5.00|
|200-day moving average||$4.34|
|Wall St. target price||$12.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.51|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||-7.58%|
|1 month (2021-09-22)||11.06%|
|3 months (2021-07-22)||30.95%|
|6 months (2021-04-22)||19.63%|
|1 year (2020-10-21)||-7.08%|
|2 years (2019-10-21)||60.50%|
|3 years (2018-10-19)||71.24%|
|5 years (2016-10-21)||89.63%|
|Revenue TTM||$7.3 million|
|Gross profit TTM||$496,981|
|Return on assets TTM||-28.11%|
|Return on equity TTM||-57.23%|
|Market capitalisation||$69.3 million|
TTM: trailing 12 months
There are currently 794,282 Biomerica shares held short by investors – that's known as Biomerica's "short interest". This figure is 18.5% down from 974,481 last month.
There are a few different ways that this level of interest in shorting Biomerica shares can be evaluated.
Biomerica's "short interest ratio" (SIR) is the quantity of Biomerica shares currently shorted divided by the average quantity of Biomerica shares traded daily (recently around 60911.196319018). Biomerica's SIR currently stands at 13.04. In other words for every 100,000 Biomerica shares traded daily on the market, roughly 13040 shares are currently held short.
However Biomerica's short interest can also be evaluated against the total number of Biomerica shares, or, against the total number of tradable Biomerica shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Biomerica's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Biomerica shares in existence, roughly 60 shares are currently held short) or 0.0756% of the tradable shares (for every 100,000 tradable Biomerica shares, roughly 76 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Biomerica.
Find out more about how you can short Biomerica stock.
We're not expecting Biomerica to pay a dividend over the next 12 months.
Biomerica's shares were split on a 1:2 basis on 13 November 1994. So if you had owned 2 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Biomerica shares – just the quantity. However, indirectly, the new 100% higher share price could have impacted the market appetite for Biomerica shares which in turn could have impacted Biomerica's share price.
Over the last 12 months, Biomerica's shares have ranged in value from as little as $3.3 up to $8.15. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Biomerica's is -0.6603. This would suggest that Biomerica's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Biomerica has bucked the trend.
Biomerica, Inc. , a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome therapy technology and diagnostic-guided therapy; Helicobacter pylori products, as well as develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.